Merck, Ridgeback File For Emergency Use Nod For COVID-19 Antiviral

Merck & Co Inc MRK has submitted an Emergency Use Authorization (EUA) application to the FDA for molnupiravir, an antiviral candidate for COVID-19.
Related: Merck COVID-19 Oral Antiviral Cuts Risk of Hospitalization, Death By 50%.
The application is seeking approval for molnupiravir in mild-to-moderate COVID-19 in adults at risk of progressing to severe COVID-19 or hospitalization.
The companies are actively working with regulatory agencies worldwide to submit applications for emergency use or marketing authorization in the coming months.
Related: Merck Inks Supply Pact With Singapore For Its Oral COVID-19 Antiviral: Reuters.
Also Read: Indian Study Shows Merck's COVID-19 Antiviral Candidate Less Effective Against Moderate Infection: Reuters.
Price Action: MRK shares are up 1.14% at $81.55 during the premarket session on the last check Monday.